Professional Documents
Culture Documents
notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
Contents
1. Executive Summary
1.1 Overview of Findings 1.2 Chapters in the Report 1.3 Research and Analysis Methods 1.4 What Are Vaccines?
3.1 Segment to Lose Market Share, but Still Record Strong Growth 3.2 Combinations Form Basis of Segment Revenues 3.3 Prevnar Franchise Represents a Quarter of the Paediatric Segments Total Value in 2012 3.3.1 Prevnar-13: Domination to Continue?
www.visiongain.com
Contents
3.3.1.1 First of the Blockbuster Vaccines 3.3.1.2 Label Extensions for Prevnar Continue 3.3.1.3 Synflorix Competing Strongly in Emerging Markets 3.3.1.4 Big Three Vaccine Manufacturers All Set to Challenge Pfizer in Pneumococcal Disease Area 3.3.1.5 How Much Room for Growth for Prevnar-13? 3.3.2 Sanofi Pasteur and GlaxoSmithKline Competing in Paediatric Combination Space 3.3.2.1 Hexaxim Boosts Sanofi Portfolio 3.3.2.2 GlaxoSmithKline Combinations Make Gains in US in 2012 3.3.2.3 Inadequacies in Pertussis and Hepatitis B Care 3.3.2.4 Room for Vaccine Competition in Those Disease Areas? 3.3.2.5 Sanofi and GSK Head-to-Head, 2013-2023 3.3.3 Competition Increases in Meningitis Vaccines Space 3.3.3.1 Menveo Label Widened in August 2013 3.3.3.2 Other Competitors for Paediatric A, C, Y and W-135 Serotypes Market 3.3.3.3 Bexsero Still to Convince EU Payers 3.3.4 Four-Disease Combination is Mercks Leading Paediatric Vaccine 3.3.4.1 Supply Issues Still Restraining ProQuad 3.3.4.2 Varivax Commercial Backbone of Combination 3.3.4.3 Mumps Immunity Waning? 3.3.4.4 Will MMR-II/ProQuad/Varivax Realise its Full Market Potential? 3.3.5 Duel for the Rotavirus Market Continues 3.3.5.1 RotaTeq Leads the Market 3.3.5.2 Rotavirus Immunisation Added to UK Schedules 3.3.5.3 New Chinese and Indian Products Come to Developing World 3.3.5.4 Will RotaTeq Hit the Blockbuster Heights? 3.3.6 Paediatric Vaccines Against Other Diseases, 2013 3.3.6.1 Japanese Encephalitis Vaccine Approved for Children 3.3.6.2 Mosquirix Records Disappointing Phase 3 Data 3.3.6.3 Sanofi Records a First in 50 Years of Dengue Research
www.visiongain.com
Contents
3.3.6.4 Two MedImmune RSV Vaccines in Development 3.3.6.5 Novartis Targeting Typhoid Opportunity 3.3.6.6 Hand, Foot and Mouth Vaccine: A Chinese Target 3.3.6.7 Anthrax Vaccines for Children? 3.3.6.8 Potential Vaccines for Autism and Diabetes 3.4 Summary: The Biggest Segment, but the Least Dynamic
www.visiongain.com
Contents
4.3.3.6 Response to H7N9 Beyond China and Taiwan 4.3.4 Universal Influenza Vaccines: A Distant Dream? 4.3.4.1 Universal Candidates Reach Phase 2 4.4 Overview: High Innovation, Low Market-Entry Barriers, High Volumes of Product Needed
www.visiongain.com
Contents
5.3.4.2 Two New Late-Stage Shingles Candidates 5.3.4.3 Other Herpesvirus R&D in Vaccines 5.3.4.4 Need for Cytomegalovirus Vaccine? 5.3.5 Other Unmet Needs in the Adult Segment 5.3.5.1 Dengue Fever the Next Target 5.3.5.2 Anthrax and Other Bio-Terror Vaccines 5.3.5.3 HIV Vaccine: 30-Year Hunt Continues After HVTN 505 5.3.5.4 Developers Interest in Malaria 5.3.5.5 Anti-Staphyloccocal Vaccines Form an Important Need 5.3.5.6 Other New Antibacterial Vaccines in Development 5.3.5.7 Important New Antiviral Vaccine Targets 5.3.5.8 Protozoans and Other Vaccine Targets 5.4 Overview: Extensive Pipeline, but Adult Immunisation Still Needs to Become More Widely Established
www.visiongain.com
Contents
6.3.2.4 Agenus In Late-Stage Trials in Melanoma and Renal Cancer 6.3.3 Other Major Solid Tumour Targets 6.3.3.1 Breast Cancer One of the Most-Crowded Areas of Therapeutic Vaccines Pipeline 6.3.3.2 Pancreatic Cancer: Major Unmet Need, Slender Pipeline 6.3.3.3 Still Several Ovarian Cancer Candidates After Abagovamab Disappointment 6.3.3.4 Several Candidates Against Glioblastoma 6.3.3.5 Other Cancer Vaccines in Development 6.3.4 Other Chronic Diseases: Vaccine Treatments for RA and Diabetes? 6.3.4.1 New Options in Chronic Neurodegenerative Diseases Pipeline 6.3.4.2 HIV: Major Therapeutic Vaccines Target 6.3.4.3 Other Chronic Viral Infections Pipeline 6.3.4.4 Cat Allergies and Other New Allergy Targets for Vaccine R&D 6.3.4.5 Addictions and Other Therapeutic Vaccine Targets 6.4 Overview: Huge Potential, but Little Market Success to Date
www.visiongain.com
Contents
8.4 Threats: Cost-Effectiveness a Harder Sell for Governments 8.5 Social Concerns: One of the Most Emotive Areas of Healthcare 8.6 Technological Developments: New Delivery Systems, New Adjuvants, 2D Barcoding and Other Innovations 8.7 Health Economics: 2700% Increase in Cost of Vaccinating a Child 8.8 Political Issues: From Bio-Defence to Polio Eradication, Governments Hold the Key to the Market
10. Conclusions
10.1 Vaccines Market Remains on Course for Steady Growth to 201 10.2 Sales Growth to Be Sustained 2018-2023 10.3 Adult Segment to Grow Twice as Fast as Paediatric Segment 10.4 Therapeutic Vaccines to Gain Importance from 2018-2023 10.5 Market Remains Heavily Consolidated 10.6 Blockbuster Products Lead the Way; Scope in Developing World 10.7 Rich Pipeline, Particularly in Therapeutic Vaccines
www.visiongain.com
Contents
10.8 Concluding Remarks
www.visiongain.com
Contents
List of Tables
Table 1.1 Currency Exchange Rates Table 2.1 Vaccines Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 2.2 Vaccines Market: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 2.3 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012 Table 2.4 Vaccines Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017 Table 2.5 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017 Table 2.6 Vaccines Market by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023 Table 2.7 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023 Table 2.8 Vaccine-Preventable Diseases and their Statistics Table 2.9 Types of Vaccine, 2013 Table 2.10 Leading Vaccine Products: Revenues ($m), Market Shares (%), 2012 Table 2.11 Leading Vaccine Products: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017 Table 2.12 Leading Vaccine Products: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023 Table 2.13 Leading Vaccine Manufacturers: Revenues ($m), Market Share (%), 2012 Table 3.1 Paediatric Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 3.2 Paediatric Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 3.3 Leading Paediatric Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Table 3.4 Selected Pipeline Products in Paediatric Vaccines Segment, 2013 Table 3.5 Paediatric Pneumococcal Vaccines Pipeline, 2013 Table 3.6 Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic): Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 3.7 Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic): Revenues ($m), AGR (%), CAGR (%), 2018-2023
www.visiongain.com
Contents
Table 3.8 Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 3.9 Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 3.10 ProQuad/ MMR-II/ Varivax: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 3.11 ProQuad/ MMR-II/ Varivax: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 3.12 RotaTeq: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 3.13 RotaTeq: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 4.1 Influenza Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 4.2 Influenza Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 4.3 Leading Influenza Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Table 4.4 Selected Pipeline Products in Influenza Vaccines Segment, 2013 Table 4.5 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 4.6 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 4.7 Selected Pipeline Seasonal Influenza Vaccine Products, 2013 Table 4.8 Selected Pipeline H5N1 Pandemic Vaccine Products, 2013 Table 4.9 Selected Pipeline H1N1 Pandemic Vaccine Products, 2013 Table 4.10 Selected Pipeline H9N2 Pandemic Vaccine Products, 2013 Table 4.11 Selected Pipeline Universal Influenza Vaccine Products, 2013 Table 5.1 Adult Prophylactic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 20122017 Table 5.2 Adult Prophylactic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 20182023 Table 5.3 Leading Adult Prophylactic Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Table 5.4 Selected Pipeline Products in Adult Prophylactic Vaccines Segment, 2013 Table 5.5 Gardasil: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 5.6 Gardasil: Revenues ($m), AGR (%), CAGR (%), 2018-2023
www.visiongain.com
Contents
Table 5.7 Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), AGR (%), CAGR (%), 20122017 Table 5.8 Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), AGR (%), CAGR (%), 20182023 Table 5.9 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 5.10 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 5.11 Selected Pipeline Meningitis Vaccines, 2013 Table 5.12 Selected Pipeline Pneumonia Vaccines, 2013 Table 5.13 Selected Pipeline TB, Diphtheria, Pertussis, Tetanus and Rotavirus Adult Vaccines, 2013 Table 5.14 Zostavax: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 5.15 Zostavax: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 5.16 Selected Pipeline for Herpesvirus Vaccines, 2013 Table 5.17 Selected Pipeline for New Adult Vaccines for Currently Vaccine-Preventable Diseases, 2013 Table 5.18 Selected Pipeline for Dengue Virus Vaccines, 2013 Table 5.19 Selected Pipeline for Anthrax and Other Potential Bio-Terrorism Agents Vaccines, 2013 Table 5.20 Selected Pipeline for HIV Vaccines, 2013 Table 5.21 Selected Pipeline for Malaria Vaccines, 2013 Table 5.22 Selected Pipeline for New Antibacterial Vaccines, 2013 Table 5.23 Selected Pipeline for New Antiviral Vaccines, 2013 Table 5.24 Selected Pipeline for Other New Adult Prophylactic Vaccines, 2013 Table 6.1 Therapeutic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017 Table 6.2 Therapeutic Vaccines Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023 Table 6.3 Leading Therapeutic Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Table 6.4 Selected Therapeutic Vaccines, 2013
www.visiongain.com
Contents
Table 6.5 Selected Pipeline Prostate Cancer Therapeutic Vaccines, 2013 Table 6.6 Selected Pipeline Lung Cancer Therapeutic Vaccines, 2013 Table 6.7 Selected Pipeline Melanoma Therapeutic Vaccines, 2013 Table 6.8 Selected Pipeline Renal Cancer Therapeutic Vaccines, 2013 Table 6.9 Selected Pipeline Colorectal Cancer Therapeutic Vaccines, 2013 Table 6.10 Selected Pipeline Haematological Cancer Therapeutic Vaccines, 2013 Table 6.11 Selected Pipeline Breast Cancer Therapeutic Vaccines, 2013 Table 6.12 Selected Pipeline Pancreatic Cancer Therapeutic Vaccines, 2013 Table 6.13 Selected Pipeline Ovarian Cancer Therapeutic Vaccines, 2013 Table 6.14 Selected Pipeline Brain Cancer Therapeutic Vaccines, 2013 Table 6.15 Selected Other Cancer Therapeutic Vaccines, 2013 Table 6.16 Selected RA and Diabetes Therapeutic Vaccines, 2013 Table 6.17 Selected AD and MS Therapeutic Vaccines, 2013 Table 6.18 Selected HIV Therapeutic Vaccines, 2013 Table 6.19 Selected Other Chronic Viral Infections Therapeutic Vaccines, 2013 Table 6.20 Selected Anti-Allergy Therapeutic Vaccines, 2013 Table 6.21 Selected Other Therapeutic Vaccines, 2013 Table 7.1 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2012 Table 7.2 Vaccines Market by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017 Table 7.3 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2017 Table 7.4 Vaccines Market by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023 Table 7.5 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2023 Table 8.1 World Vaccines Market: Strengths and Weaknesses, 2013 Table 8.2 World Vaccines Market: Opportunities and Threats, 2013 Table 8.3 World Vaccines Market: STEP Analysis, 2013-2023
www.visiongain.com
Contents
List of Figures
Figure 2.1 Vaccines Market: Revenues ($m), 2012-2023 Figure 2.2 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2012 Figure 2.3 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2017 Figure 2.4 Vaccines Market Breakdown by Segment: Revenues ($m), Market Share (%), 2023 Figure 2.5 Vaccines Market Breakdown by Segment: Revenues ($m), 2012-2023 Figure 2.6 Vaccines Market Breakdown by Segment: Revenues ($m), 2012, 2017, 2023 Figure 2.7 Leading Vaccine Products: Revenues ($m), Market Share (%), 2012 Figure 2.8 Leading Vaccine Products: Revenues ($m), 2012-2023 Figure 2.9 Leading Vaccine Manufacturers: Revenues ($m), Market Share (%), 2012 Figure 3.1 Paediatric Vaccines Segment: Revenues ($m), 2012-2023 Figure 3.2 Global Mortality Due to VPDs in Children Under Five, Breakdown by Disease (%), 2008 Figure 3.3 Leading Paediatric Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Figure 3.4 Leading Paediatric Pneumococcal Vaccine Products: Market Share (%), 2012 Figure 3.5 Prevnar Revenue Breakdown by Segment (Paediatric and Adult Prophylactic): Revenues ($m), 2012-2023 Figure 3.6 Pentacel/Pediacel/Pentaxim/Others; Infanrix/Pediarix/Others: Revenues ($m), 20122023 Figure 3.7 ProQuad/ MMR-II/ Varivax: Revenues ($m), 2012-2023 Figure 3.8 Division of Rotavirus Vaccine Market (%), 2012 Figure 3.9 RotaTeq: Revenues ($m), 2012-2023 Figure 3.10 Drivers and Restraints for Paediatric Vaccines, 2013 Figure 4.1 Influenza Vaccines Segment: Revenues ($m), 2012-2023 Figure 4.2 Leading Influenza Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Figure 4.3Fluzone/Panenza/Humenza/Intanza/ IDflu/Emerflu/Others: Breakdown by Seasonal and Pandemic Revenues ($m), 2010-2012
www.visiongain.com
Contents
Figure 4.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($m), 2012-2023 Figure 4.5 Drivers and Restraints for Influenza Vaccines, 2013 Figure 5.1 Adult Prophylactic Vaccines Segment: Revenues ($m), 2012-2023 Figure 5.2 Leading Adult Prophylactic Vaccine Products: Revenues ($m), Segment Market Share (%), 2012 Figure 5.3 Division of HPV Vaccine Market (%), 2012 Figure 5.4 Gardasil: Revenues ($m), 2012-2023 Figure 5.5 Engerix/ Fendrix/ Havrix/ Twinrix/ Ambirix: Revenues ($m), 2012-2023 Figure 5.6 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($m), 2012-2023 Figure 5.7 Zostavax: Revenues ($m), 2012-2023 Figure 5.8 Drivers and Restraints for Adult Prophylactic Vaccines, 2013 Figure 6.1 Therapeutic Vaccines Segment: Revenues ($m), 2012-2023 Figure 6.2 Leading Therapeutic Vaccine Products: Revenues ($m), Segment Market Shares (%), 2012 Figure 6.3 Drivers and Restraints for Therapeutic Vaccines, 2013 Figure 7.1 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2012 Figure 7.2 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2017 Figure 7.3 Vaccines Market Breakdown by Region: Revenues ($m), Market Share (%), 2023 Figure 7.4 Vaccines Market Breakdown by Region: Revenues ($m), 2012-2023 Figure 7.5 Vaccines Market Breakdown by Regional Bloc: Revenues ($m), 2012-2023 Figure 7.6 Vaccines Market Breakdown by Region: Revenues ($m), 2012, 2017, 2023 Figure 7.7 US Vaccines Market: Revenues ($m), 2012-2023 Figure 7.8 EU5 Vaccines Market: Revenues ($m), 2012-2023 Figure 7.9 Japanese Vaccines Market: Revenues ($m), 2012-2023 Figure 7.10 BRIC Nations Vaccines Market: Revenues ($m), 2012-2023 Figure 7.11 Rest of the World Vaccines Market: Revenues ($m), 2012-2023 Figure 10.1 World Vaccines Market: Revenues ($m), 2012-2017 Figure 10.2 World Vaccines Market: Revenues ($m), 2018-2023 Figure 10.3 World Vaccines Market, Breakdown by Segment: Revenues ($m), 2012-2017 Figure 10.4 World Vaccines Market, Breakdown by Segment: Revenues ($m), 2018-2023
www.visiongain.com
Contents
Abbott Laboratories Abbott Laboratories AbbVie Acambis ACE Biosciences Activartis Biotech Adamis Pharmaceuticals Aduro BioTech Advaxis Aeras Aeras Global TB Vaccine Foundation Affiris Agency for Science, Technology and Research (Singapore) Agenus Akela Pharma ALK Abello Allergy Therapeutics Allertein Therapeutics Alnylam AlphaVax Altravax American Academy of Pediatrics Amgen Antigen Discovery Antigen Express Antigenics Argos Therapeutics Astellas Pharma
www.visiongain.com
Contents
AstraZeneca Augmenta Biologicals AuRx AVAX Technologies Baxter Healthcare Bayer HealthCare Bayhill Therapeutics Beijing Key Yuan Xinhai Pharmaceutical Beijing Vigoo Biological Bellicum Pharmaceuticals Bharat Biotech Biken Japan Bill & Melinda Gates Foundation Bio-Manguinhos BiondVax Bionor Pharma BioNTech BioSante Pharmaceuticals Biotech Synergy Biovest International BN ImmunoTherapeutics (Bavarian Nordic) Boston Children's Hospital BravoBio Butantan Cadila Pharma Cancer Advances Celldex Therapeutics CEL-SCI Celtic Pharma Center of Molecular Immunology (Cuba)
www.visiongain.com
Contents
Centers for Disease Control (CDC) CG Therapeutics Chemo-Sero-Therapeutic Research Institute Chengdu Institute China National Biotech Group (CNBG) China NT Pharma Group Chinese Centre for Disease Control Chinese State Food and Drug Administration (SFDA) Chiron Circassia Colby Pharmaceutical Columbia University Cosmo Pharmaceuticals Crucell CSL Biotherapies Cubas Center of Molecular Immunology CureVac Cytokine PharmaSciences Cytos Biotechnology Daiichi Sankyo DBV Technologies Dendreon Denka Seiken Company Desmond Tutu TB Centre Diabetes UK Diamyd Dynavax DynPort Vaccine Company Eisai Elea Laboratories
www.visiongain.com
Contents
EMD Serono Emergent BioSolutions Endocyte Epeius Biotechnologies Erasmus Medical Centre Etubics European Medicines Agency (EMA) Evans Medical Food and Drug Administration (US FDA) Galena Biopharma GAVI Alliance GE Healthcare GeneCure Biotechnologies Genetic Immunity Genocea Biosciences GenPhar GenVec GeoVax Labs Geron GlaxoSmithKline (GSK) Glide Pharma Gliknik Global Health Innovative Technology Fund (GHIT Fund) GlobeImmune Gradalis Greer Laboratories Hawaii Biotech Health Protection Agency (HPA) Heat Biologics Helmholtz Centre for Infection Research
www.visiongain.com
Contents
iBio Ichor Medical Systems immatics biotechnologies Immune Response Biopharma Immune Targeting Systems Immunitor ImmunoCellular Therapeutics Immunocore ImmunoFrontier Immunomic Therapeutics Immunotope Immunovaccine Immunovative Therapies ImmusanT Infectious Diseases Research Institute Inovio Pharmaceuticals Intercell Intercell USA International AIDS Vaccine Initiative (IAVI) International Federation of Pharma Manufacturers and Associations (IFPMA) International Medica Foundation Inviragen J. Craig Venter Institute Janssen Alzheimer Immunotherapy JN-International Medical Johnson & Johnson Joint Committee on Vaccination and Immunisation (JCVI, UK) KAEL-GemVax Karolinska Institute Kitasato Institute
www.visiongain.com
Contents
Korean Ministry of Health and Welfare La Jolla Institute for Allergy & Immunology Life Technologies LigoCyte Pharmaceuticals Liquidia Technologies London School of Hygiene and Tropical Medicine MabVax Therapeutics Max Planck Society MaxCyte Medecins Sans Frontieres (MSF) Medicago MedImmune Memgen Menarini Merck & Co. Merck Serono Meridian Biosciences Mitsubishi Tanabe Pharma Momotaro-Gene Nabi Biopharmaceuticals NanoBio Nanotherapeutics National Administration of Medicines, Food and Medical Technology (ANMAT, Argentina) Natrix Separations NewLink Genetics Northwest Biotherapeutics Novadigm Therapeutics Novartis NovaRx Novavax
www.visiongain.com
Contents
Novo Energies Nuron Biotech NuVax Therapeutics Nypro Healthcare Okairos OncoPep Oncothyreon Opal Therapeutics Opexa Therapeutics Opko Health Optimer Pharmaceuticals Orban Biotech Oregon Health and Science University, Vaccine and Gene Therapy Institute Oxford BioMedica PaxVax Petrovax Pfizer PharmAthene Pique Therapeutics Polynoma Prima Biomed Profectus Biosciences Progenics Pharmaceuticals Protein Sciences PsiOxus Therapeutics Quantum Immunologics Quest PharmaTech Sanaria Sanofi Sanofi Pasteur
www.visiongain.com
Contents
Sarepta SciVac Scripps Research Institute Selecta Biosciences Serum Institute of India Shanghai BravoBio Shanghai Pharma Shantha Biotech Shionogi Sinopharm Group Sinovac Biotech Soligenix South African Tuberculosis Vaccine Initiative (SATVI) Stallergenes Stemline Therapeutics Sumagen Sunovion Pharmaceuticals Takeda TapImmune TD Vaccines Tekmira Tesco Tetragenetics Teva Pharmaceutical industries Theraclone Sciences Thymon Topaz Pharmaceuticals Transgene TVAX Biomedical UK Joint Committee on Vaccination and Immunisation
www.visiongain.com
Contents
UMN Pharma UNICEF United Biomedical Universidad de Chile Universit Laval University of Cape Town University of Guelph University of London University of Minnesota's Centre for Infectious Disease Research and Policy University of Queensland University of Toronto US National Biodefence Science Board US Naval Medical Research Center Utrecht University Vaccine Research Center (NIAID) Vaccine Technologies Vaccinogen Vakzine Projekt Management Valneva Vanderbilt University Vaxart Vaxin VaxInnate VaxOnco Vical Vivalis Vodafone Walter Reed Army Institute World Health Organisation (WHO) Xcellerex
www.visiongain.com
Contents
Zhejiang Tianyuan Zuellig Pharma
www.visiongain.com
Table 5.5 Gardasil: Revenues ($m), AGR (%), CAGR (%), 2012-2017
2012 Revenues ($m ) AGR (%) CAGR (%,2012-2017)
Source: visiongain 2013
2013 1755 -7
2014 1823 4
2015 1875 3
1895
www.visiongain.com
Page 105
2022 680 -6
1276 -11
www.visiongain.com
Page 106